The suppression of these receptors and augmentation of PTGER4, strongly suggest that PGE2, produced via PTGS and PTGES2, is a driver of endometrial tumour development via the activation of PTGER4 and initiation of cAMP signalling. The gene discussed is PTGER4; the disease is endometrium neoplasm.